-
Valeant Withdraws Prior Guidance, Announces CEO Mike Pearson Will Return To Work Immediately Following Pneumonia Scare
Monday, February 29, 2016 - 8:35am | 250Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged more than 8 percent early Monday morning after the company issued a business update over the weekend. Valeant confirmed that Michael Pearson will resume his role as CEO, effective immediately. The executive was hospitalized...
-
Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers
Friday, May 1, 2015 - 12:15pm | 403Read More...Viking Global Investors released a quarterly update to its investors on April 27, noting new positions in Google Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) and Cheniere Energy, Inc. (NYSE: LNG). The letter, written by CEO and co-founder Ole Andreas Halvorsen, noted that despite the recent stake,...
-
U.S. Produced Fewer Than Expected Jobs In October
Sunday, November 9, 2014 - 9:16pm | 666Read More...U.S. stocks were little changed to close last week as U.S. data showed the economy created fewer than expected jobs in October. However, the unemployment rate declined to a six-year low of 5.8 percent. The unemployment rate continues to improve, inching closer to the Fed's 5.4 percent to 5....
-
Will Actavis Win Competition For Allergan's Affection?
Thursday, October 16, 2014 - 11:10am | 839Read More...Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.” In...
-
#PreMarket Primer: Wednesday, September 24: US Economy Looking Strong In The Third Quarter
Wednesday, September 24, 2014 - 7:13am | 1272Read More...Data out on Tuesday confirmed that the U.S. economy is on a firm path to recovery as reports showed that manufacturing data neared a four and a half year high in September. The nation’s flash PMI was 57.9 in September, unchanged from August’s reading. However, the U.S. housing...
-
#PreMarket Primer: Tuesday, September 23: First Airstrikes In Syria Begin
Tuesday, September 23, 2014 - 7:28am | 1100Read More...The U.S., alongside its Gulf Arab allies, began the first in a series of airstrikes against Islamic State militants in Syria on Tuesday. Reuters reported that Saudi Arabia, the United Arab Emirates, Jordan and Bahrain are all taking part with Qatar providing support as needed. The strike is...
-
Cramer's Watchlist: Target And Lowe's Rebound As Hertz Remains In The Red
Wednesday, August 20, 2014 - 12:28pm | 537Read More...Mixed earnings results led to some volatile movement Wednesday morning. Jim Cramer noted a handful of stocks in pre-market session. Below is a look at how stocks in Cramer's "watchlist" were performing heading into Wednesday's afternoon trading session. $TGT, $HTZ, $AGN--...
-
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
Tuesday, August 19, 2014 - 4:35pm | 2619Read More...U.S. stocks rose as geopolitical events took a back seat and investors found positives in housing and consumer price index data released Tuesday. The markets followed the lead of Apple which closed at an all-time split-adjusted high of $100.53. Earnings from Home Depot and TJX Companies also...
-
5 Drug Companies Profiting From Generics
Monday, August 4, 2014 - 8:29am | 864Read More...Leading generic drug maker Teva Pharmaceutical (NYSE: TEVA) posted better than expected earnings last week and raised its full-year profit forecast. There was plenty for investors to be concerned about, though. Sales of its best-selling product, Copaxone, were down for the quarter, and activist...
-
Dow Flirts With 17,000, S&P 500 Inches Closer To 2,000 In First Trading Day Of The Third Quarter
Tuesday, July 1, 2014 - 4:48pm | 2089Read More...U.S. stocks were higher as the back-end of 2014 kicked off. The Dow came within less than two points of reaching the 17,000 mark as investors and traders found plenty of positives in a better-than-expected June auto sales and an expansion in U.S. manufacturing. The S&P 500 also traded at...
-
UPDATE: Piper Jaffray Raises PT on Salix Pharmaceuticals from $47 to $50
Tuesday, August 9, 2011 - 9:21am | 111Read More...Piper Jaffray has published a research report on Salix Pharmaceuticals (NASDAQ: SLXP) raising the price target on the pharmaceutical developer. In the report, Piper Jaffray wrote, "Last night, Salix reported 2Q11 non-GAAP diluted EPS of $0.54, ahead of the Street estimate of $0.49. Xifaxan sales...
-
UPDATE: Duncan-Williams Color on Salix Pharmaceuticals Upgrade
Tuesday, July 5, 2011 - 8:31am | 102Read More...Duncan-Williams, which upgraded shares of Salix Pharmaceuticals (NASDAQ: SLXP), is providing some color on the stock. “We use DCF analysis (11.5% WACC, down from 12.5% previously, and a 1% terminal growth rate) to arrive at our price target,” Duncan-Williams writes. “We believe the IBS situation...
-
Duncan Williams Upgrades Salix Pharmaceuticals To Buy, $47 PT
Tuesday, July 5, 2011 - 7:10am | 26Read More...Duncan Williams has upgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Hold to Buy and has established a $47 price target.
-
Piper Jaffray Reiterates Overweight Rating On Salix Pharmaceuticals
Monday, June 20, 2011 - 7:45am | 165Read More...According to Piper Jaffray, Salix Pharmaceuticals (NASDAQ: SLXP) shares reflect minimal expectations for Xifaxan550 in irritable bowel syndrome (IBS) ahead of the 6/20/11 FDA meeting to explore a path forward. Piper Jaffray said that an outcome involving SLXP running a non-randomized study would...
-
Duncan-Williams Maintains Buy Rating On Salix
Thursday, May 12, 2011 - 7:44am | 143Read More...According to Duncan-Williams, Salix Pharmaceuticals (NASDAQ: SLXP) Buy rating is maintained. Duncan-Williams said that it is even more convinced that designing and conducting a prospective trial for Xifaxan IBS is extremely difficult and that the company will not undertake the effort. “Dr....
